Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy

AIEOP (Italian Association of Pediatric Hematology and Oncology) and Pediatric Hodgkin’s Lymphoma working Group

Research output: Contribution to journalArticle

Abstract

Identify a subset of early-stage HL children (GR1) curable with limited chemotherapy+/-radiotherapy; improve outcome of intermediate (GR2) and high-risk (GR3) patients; establish impact of response to chemotherapy evaluated with conventional imaging (CI). One hundred and sixty GR1-patients received 3ABVD + involved-field (IF) low-dose (LD) (20 Gy) irradiation if mediastinal mass or partial response (PR) after chemotherapy. Eighty-five GR2- and 315 GR3-patients received 4 and 6 COPP/ABV + IFRT, respectively. The 63 GR1 patients spared from radiotherapy had 15-year survival and EFS of 100 and 84.5%, respectively. The GR2 and GR3 15-year FFP were 84.7 and 78.6%, respectively. No different prognosis for patients in CR or PR evaluated during and after chemotherapy was observed. In conclusion, low-risk patients in CR may be successfully treated with radiation-free, low-intensity chemotherapy. Good, but less satisfactory, results were registered in GR2 and GR3. Response evaluated with CI is not a prognostic factor, but permits identification of low-risk patients who can avoid radiotherapy.

Original languageEnglish
Pages (from-to)2612-2621
Number of pages10
JournalLeukemia and Lymphoma
Volume59
Issue number11
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Hodgkin Disease
Radiotherapy
Drug Therapy
Radiation
Survival

Cite this

Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy. / AIEOP (Italian Association of Pediatric Hematology and Oncology) and Pediatric Hodgkin’s Lymphoma working Group.

In: Leukemia and Lymphoma, Vol. 59, No. 11, 11.2018, p. 2612-2621.

Research output: Contribution to journalArticle

AIEOP (Italian Association of Pediatric Hematology and Oncology) and Pediatric Hodgkin’s Lymphoma working Group. / Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 11. pp. 2612-2621.
@article{2a64d03e477944769457b33d5592814f,
title = "Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy",
abstract = "Identify a subset of early-stage HL children (GR1) curable with limited chemotherapy+/-radiotherapy; improve outcome of intermediate (GR2) and high-risk (GR3) patients; establish impact of response to chemotherapy evaluated with conventional imaging (CI). One hundred and sixty GR1-patients received 3ABVD + involved-field (IF) low-dose (LD) (20 Gy) irradiation if mediastinal mass or partial response (PR) after chemotherapy. Eighty-five GR2- and 315 GR3-patients received 4 and 6 COPP/ABV + IFRT, respectively. The 63 GR1 patients spared from radiotherapy had 15-year survival and EFS of 100 and 84.5{\%}, respectively. The GR2 and GR3 15-year FFP were 84.7 and 78.6{\%}, respectively. No different prognosis for patients in CR or PR evaluated during and after chemotherapy was observed. In conclusion, low-risk patients in CR may be successfully treated with radiation-free, low-intensity chemotherapy. Good, but less satisfactory, results were registered in GR2 and GR3. Response evaluated with CI is not a prognostic factor, but permits identification of low-risk patients who can avoid radiotherapy.",
author = "{AIEOP (Italian Association of Pediatric Hematology and Oncology) and Pediatric Hodgkin’s Lymphoma working Group} and Roberta Burnelli and Simona Rinieri and Roberto Rondelli and Alessandra Todesco and Maurizio Bianchi and Alberto Garaventa and Marco Zecca and Paolo Indolfi and Valentino Conter and Nicola Santoro and Maurizio Aric{\`o} and Simone Cesaro and Salvatore D'amico and Piero Farruggia and {De Santis}, Raffaela and Franco Locatelli and Pileri, {Stefano A} and Giovanni Scarzello and Maurizio Mascarin and Vico Vecchi",
year = "2018",
month = "11",
doi = "10.1080/10428194.2018.1435872",
language = "English",
volume = "59",
pages = "2612--2621",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy

AU - AIEOP (Italian Association of Pediatric Hematology and Oncology) and Pediatric Hodgkin’s Lymphoma working Group

AU - Burnelli, Roberta

AU - Rinieri, Simona

AU - Rondelli, Roberto

AU - Todesco, Alessandra

AU - Bianchi, Maurizio

AU - Garaventa, Alberto

AU - Zecca, Marco

AU - Indolfi, Paolo

AU - Conter, Valentino

AU - Santoro, Nicola

AU - Aricò, Maurizio

AU - Cesaro, Simone

AU - D'amico, Salvatore

AU - Farruggia, Piero

AU - De Santis, Raffaela

AU - Locatelli, Franco

AU - Pileri, Stefano A

AU - Scarzello, Giovanni

AU - Mascarin, Maurizio

AU - Vecchi, Vico

PY - 2018/11

Y1 - 2018/11

N2 - Identify a subset of early-stage HL children (GR1) curable with limited chemotherapy+/-radiotherapy; improve outcome of intermediate (GR2) and high-risk (GR3) patients; establish impact of response to chemotherapy evaluated with conventional imaging (CI). One hundred and sixty GR1-patients received 3ABVD + involved-field (IF) low-dose (LD) (20 Gy) irradiation if mediastinal mass or partial response (PR) after chemotherapy. Eighty-five GR2- and 315 GR3-patients received 4 and 6 COPP/ABV + IFRT, respectively. The 63 GR1 patients spared from radiotherapy had 15-year survival and EFS of 100 and 84.5%, respectively. The GR2 and GR3 15-year FFP were 84.7 and 78.6%, respectively. No different prognosis for patients in CR or PR evaluated during and after chemotherapy was observed. In conclusion, low-risk patients in CR may be successfully treated with radiation-free, low-intensity chemotherapy. Good, but less satisfactory, results were registered in GR2 and GR3. Response evaluated with CI is not a prognostic factor, but permits identification of low-risk patients who can avoid radiotherapy.

AB - Identify a subset of early-stage HL children (GR1) curable with limited chemotherapy+/-radiotherapy; improve outcome of intermediate (GR2) and high-risk (GR3) patients; establish impact of response to chemotherapy evaluated with conventional imaging (CI). One hundred and sixty GR1-patients received 3ABVD + involved-field (IF) low-dose (LD) (20 Gy) irradiation if mediastinal mass or partial response (PR) after chemotherapy. Eighty-five GR2- and 315 GR3-patients received 4 and 6 COPP/ABV + IFRT, respectively. The 63 GR1 patients spared from radiotherapy had 15-year survival and EFS of 100 and 84.5%, respectively. The GR2 and GR3 15-year FFP were 84.7 and 78.6%, respectively. No different prognosis for patients in CR or PR evaluated during and after chemotherapy was observed. In conclusion, low-risk patients in CR may be successfully treated with radiation-free, low-intensity chemotherapy. Good, but less satisfactory, results were registered in GR2 and GR3. Response evaluated with CI is not a prognostic factor, but permits identification of low-risk patients who can avoid radiotherapy.

U2 - 10.1080/10428194.2018.1435872

DO - 10.1080/10428194.2018.1435872

M3 - Article

C2 - 29448858

VL - 59

SP - 2612

EP - 2621

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -